L-Leucine.|61-90-5|(L-亮氨酸; Leucine)-陌孚医药/Medlife

您当前的位置：

L-Leucine. (Synonyms: L-亮氨酸; Leucine)

目录号: PC18883 纯度: ≥98%

CAS No. :61-90-5

商品编号	规格	价格	会员价	是否有货	数量
PC18883-50mg	50mg	¥360.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

L-Leucine.

中文别名

L-亮氨酸;L-白氨酸;L-2-氨基-4-甲基戊酸;L-亮氨酸（白氨酸）;CultureSure L-亮氨酸,无动物源成分;L-Leucine L-亮氨酸;L亮氨酸;L-亮氨酸 (白氨酸);L-亮氨酸 (食品级)(CP2010);L-亮氨酸 L-Leucine;L-亮氨酸 USP标准品;L-亮氨酸(RG);L-亮氨酸（标准品）;L-亮氨酸标准品;L-亮氨酸对照品;L-亮胺酸;亮氨酸;亮氨酸 EP标准品;(S)-2-氨基-4-甲基戊酸;2-氨基-4-甲基戊酸;L-α-氨基异丁;L-α-氨基异丁基醋酸;L-α-氨基异己酸;L-白氨酸,L-闪白氨基酸,氨基异己酸;L-高氨酸;L-闪白氨基酸;α-氨基-γ-甲基戊酸;α-氨基异己酸;氨基异己酸;白氨酸;白氨酸标准品

英文名称

Leucine

英文别名

L-Leucine;(S)-2-Amino-4-methylpentanoic acid;H-Leu-OH;L-Leu;L(+)LEUCINE;LEUCINE, L-(P);LEUCINE, L-(RG);(L)-leucine;(S)-(+)-leucine;(S)-2-amino-4-methyl-pentanoic acid;[14C]-L-(+)-Leucine;[14C]-L-Glutamic acid;[3H]-L-Glutamic acid;Aciglut;GLU;Glusate;GLUTACID;glutamic;Glutaton;H-GLU-OH;H-L-GLU-OH;L-(+)-glutamic acid;L-2-AMino-4-Methylpentanoic acid;L-GLU;L-α-AMinoisobutylacetic acid;L-α-AMino-γ-Methylvaleric acid;amino acid;leucine;(S)-Leucine;(2S)-2-amino-4-methylpentanoic acid;Leucin;L-Norvaline, 4-methyl-;(S)-2-Amino-4-methylvaleric acid;L-leucin;L-alpha-Aminoisocaproic acid;Leucin [German];LEUCINE, L-;Leucine (VAN);leu;Leucinum;(2S)-alpha-leucine;L-(+)-Leucine;L-(-)-2-Amino-4-methylpentanoic acid;Leucinum [INN-Latin];2-amino-4-methylvaleric acid;Leucine [USAN:INN];L-Leuzin;Leucina [INN-Spanish];Leucina [Latin,Spanish];alpha-Aminoisoca

Cas No.

61-90-5

分子式

C₆NO₂H₁₃

分子量

131.17

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.

性状

Solid

IC50 & Target[1][2]

mTORC1

Human Endogenous Metabolite

Microbial Metabolite

体外研究(In Vitro)

L-Leucine (10 mM) treatment impairs endocrine progenitor cell development.
In E13.5 rat pancreatic explants, in absence of added L-Leucine, Ngn3 mRNA levels increased after 1 day of culture, peaked on day 3, and then decreased. When L-Leucine is added, a dramatic decrease is observed in Ngn3 mRNA levels. This decrease in Ngn3 mRNA levels was paralleled by a decrease in the number of Ngn3-expressing cells (4728±408 vs. 959±28; P<0.01). Finally, L-Leucine also caused a dose-dependent repressive effect on the mRNA levels of the three genes, namely Ngn3, its target Insm1, and insulin.
Leucine stimulates protein synthesis in skeletal muscle of neonatal pigs by enhancing mTORC1 activation. L-Leucine increases intracellular HIF-1α levels and activates the HIF-1α signaling pathway, and these two effects are mediated by the mTOR signaling pathway. This process results in Ngn3 repression and, consequently, decreases β-cell differentiation.
L-leucine stimulates mTORC1 by through a mechanism that involves the leucyl tRNA synthase promoting the activity of GTP activating proteins that act on mTORC1.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

L-Leucine (24 g/kg diet) combined with Resveratrol (12.5 mg/kg diet) to diet-induced obese (DIO) mice increases adipose Sirt1 activity.
Combination results in significant reductions in body weight, weight gain, visceral adipose tissue mass, fat oxidation and heat production in mice.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old male c57/BL6 mice (fed a high-fat diet with fat to induce obesity)
Dosage:	24 g/kg diet; Resveratrol (low dose; 12.5 mg/kg diet)
Administration:	6 weeks
Result:	Treatment in combination with Resveratrol (low dose; 12.5 mg/kg diet) resulted in significant reductions in body weight, weight gain, visceral adipose tissue mass, fat oxidation and heat production, and an associated decrease in respiratory exchange ratio (RER), especially in the dark (feeding) cycle.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

ClinicalTrial

结构分类

Amino acids

来源

参考文献

[1]. Baoshan Xu, et al. Stimulation of mTORC1 with L-leucine rescues defects associated with Roberts syndrome. PLoS Genet. 2013;9(10):e1003857. [Information]

[2]. Bruckbauer A, et al. Synergistic effects of leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes and mice. Nutr Metab (Lond). 2012 Aug 22;9(1):77. [Information]

[3]. Rachdi L, et al. L-leucine alters pancreatic β-cell differentiation and function via the mTor signaling pathway. Diabetes. 2012 Feb;61(2):409-17. [Information]

溶解度数据

体外研究:

H₂O : 8.33 mg/mL (63.51 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	7.6237 mL	38.1185 mL	76.2369 mL
5 mM	1.5247 mL	7.6237 mL	15.2474 mL
10 mM	0.7624 mL	3.8118 mL	7.6237 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： PBS
Solubility: 6.25 mg/mL (47.65 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation